STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] Zeo ScientifiX, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Zeo ScientifiX, Inc. filed an 8-K reporting that on October 23, 2025 it issued a press release stating the company is prepared to capitalize on the potentially rapid expansion of Florida’s regenerative medicine market following enactment of the new state stem cell law, SB 1768, effective July 1, 2025.

The press release is furnished as Exhibit 99.1 and incorporated by reference.

Positive
  • None.
Negative
  • None.
false 0001557376 0001557376 2025-10-23 2025-10-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): October 23, 2025

 

ZEO SCIENTIFIX, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   000-55008   47-4180540
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

3321 College Avenue, Suite 246
Davie, Florida

  33314
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (888) 963-7881

 

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class   Trading Symbol   Name of each exchange on which registered
None   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

As used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the Company,” “ZEO,” “we,” “us” and “our” refer to Zeo ScientifiX, Inc.

 

Item 8.01Other Events.

 

On October 23, 2025 ZEO issued a press release announcing that the Company is prepared to capitalize on the potentially rapid expansion of Florida’s regenerative medicine market following enactment of the new state stem cell law, SB 1768, effective July 1, 2025.

 

A copy of the press release is included as Exhibit 99.1 to this Report and is incorporated herein by reference.

 

Item 9.01Financial Statements and Exhibits.

 

(d)Exhibits

 

Exhibit No.   Description
99.1   Press Release, dated October 23, 2025
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: October 23, 2025 ZEO SCIENTIFIX, INC.
     
  By: /s/ Ian T. Bothwell
   

Ian T. Bothwell

Interim Chief Executive Officer and Chief Financial Officer

 

2

FAQ

What did Zeo ScientifiX (ZEOX) file?

An 8-K reporting a press release about Florida’s stem cell law SB 1768 and the company’s readiness to capitalize on market expansion.

What was announced in the ZEOX press release?

Zeo ScientifiX said it is prepared to capitalize on Florida’s regenerative medicine market following SB 1768.

When does Florida’s SB 1768 become effective?

The filing states SB 1768 is effective on July 1, 2025.

When was the press release issued by ZEOX?

The press release was issued on October 23, 2025.

Is the press release included with the 8-K?

Yes. It is furnished as Exhibit 99.1 and incorporated by reference.

Does ZEOX list any securities on an exchange?

The filing lists None under exchange-traded securities.
ZEO ScientifiX

OTC:ZEOX

ZEOX Rankings

ZEOX Latest News

ZEOX Latest SEC Filings

ZEOX Stock Data

9.87M
3.56M
45.68%
Biotechnology
Healthcare
Link
United States
Davie